NeuroMetrix (NASDAQ:NURO) Coverage Initiated at StockNews.com

Equities research analysts at StockNews.com assumed coverage on shares of NeuroMetrix (NASDAQ:NURO) in a report released on Monday. The firm set a “sell” rating on the medical device company’s stock.

NeuroMetrix Stock Down 6.8 %

NASDAQ:NURO opened at $3.55 on Monday. NeuroMetrix has a 52 week low of $2.66 and a 52 week high of $4.73. The stock’s 50-day moving average price is $4.04 and its 200-day moving average price is $3.88. The stock has a market capitalization of $7.21 million, a PE ratio of -0.64 and a beta of 2.29.

NeuroMetrix (NASDAQ:NURO) last released its earnings results on Tuesday, August 6th. The medical device company reported ($0.74) EPS for the quarter. NeuroMetrix had a negative return on equity of 41.74% and a negative net margin of 181.04%. The company had revenue of $0.77 million for the quarter.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.